Grant: Catalyst Grant: Personalized Health Catalyst Grants
University of Toronto
$199,619.00
Do men and women differ in how pharmacogenetics optimizes smoking cessation therapy?
FY 2017-18
Summary
Cigarette smoking is a leading cause of preventable illness and death in Canada; strategies to optimize smoking cessation success are key to improving healthcare delivery and reducing tobacco-associated economic and personal costs. There are three medications to aid cessation: nicotine replacement therapy, bupropion, and varenicline. Genetic variation in specific enzymes and transporters that act on these medications influences drug levels, treatment response, and adverse effects. There are also sex differences (via hormones) on the activity of these enzymes and transporters as well as sex and gender differences in response to and success of cessation therapies; for example, women have lower quit rates on nicotine replacement therapy and bupropion, and higher quit rates on varenicline, compared to men.
This proposal will examine, for the first time, sex and gender differences in the known impact of genetics on treatment response, providing a better understanding of how sex and gender can be integrated into genomics-based strategies for personalizing smoking cessation. We propose to analyze existing data from ~1,700 smokers (822 males and 873 females) that participated in our placebo-controlled clinical trials involving the nicotine patch, bupropion, and varenicline. Participants have been genotyped for key genetic variants in relevant metabolism and transporter genes, and drug levels have been assessed. The current project will explicitly test (using biostatistical tests) whether genetic effects on enzyme activity, treatment drug levels, and smoking cessation (and adverse effects) differ for men and women. We will also examine sex and gender differences in the genetic effects on withdrawal/depressive symptoms and smoking cessation-associated weight gain. Our studies will improve the tailoring of smoking cessation treatment in both men and women, which will reduce the extensive morbidity, mortality, and economic costs associated with cigarette smoking.
Department
Program
Catalyst Grant: Personalized Health Catalyst Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
365094
Name
Tyndale Rachel F
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Clinical
Prcname2
Personalized Health - sex-drug-gene relationships
Projecttitle
Do men and women differ in how pharmacogenetics optimizes smoking cessation therapy?
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$199,619
Cihrequipment2
$0
Programname2
Catalyst Grant: Personalized Health Catalyst Grants
Keyworddelim
Gender Differences; Medication Adherence; Personalized Medicine; Pharmacogenetics; Pharmacokinetic Variation; Sex Differences; Smoking Cessation
Abstract
Cigarette smoking is a leading cause of preventable illness and death in Canada; strategies to optimize smoking cessation success are key to improving healthcare delivery and reducing tobacco-associated economic and personal costs. There are three medications to aid cessation: nicotine replacement therapy, bupropion, and varenicline. Genetic variation in specific enzymes and transporters that act on these medications influences drug levels, treatment response, and adverse effects. There are also sex differences (via hormones) on the activity of these enzymes and transporters as well as sex and gender differences in response to and success of cessation therapies; for example, women have lower quit rates on nicotine replacement therapy and bupropion, and higher quit rates on varenicline, compared to men.
This proposal will examine, for the first time, sex and gender differences in the known impact of genetics on treatment response, providing a better understanding of how sex and gender can be integrated into genomics-based strategies for personalizing smoking cessation. We propose to analyze existing data from ~1,700 smokers (822 males and 873 females) that participated in our placebo-controlled clinical trials involving the nicotine patch, bupropion, and varenicline. Participants have been genotyped for key genetic variants in relevant metabolism and transporter genes, and drug levels have been assessed. The current project will explicitly test (using biostatistical tests) whether genetic effects on enzyme activity, treatment drug levels, and smoking cessation (and adverse effects) differ for men and women. We will also examine sex and gender differences in the genetic effects on withdrawal/depressive symptoms and smoking cessation-associated weight gain. Our studies will improve the tailoring of smoking cessation treatment in both men and women, which will reduce the extensive morbidity, mortality, and economic costs associated with cigarette smoking.
Competitiondate
201706
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Tyndale, Rachel F
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $199,619~ $0~